CN101657213B - 用于增强t细胞应答的方法 - Google Patents

用于增强t细胞应答的方法 Download PDF

Info

Publication number
CN101657213B
CN101657213B CN200880012207.3A CN200880012207A CN101657213B CN 101657213 B CN101657213 B CN 101657213B CN 200880012207 A CN200880012207 A CN 200880012207A CN 101657213 B CN101657213 B CN 101657213B
Authority
CN
China
Prior art keywords
application
antigen
dosage
cells
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880012207.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN101657213A (zh
Inventor
托马斯·昆迪希
阿德里安·博特
肯特·安德鲁·史密斯
裘志勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of CN101657213A publication Critical patent/CN101657213A/zh
Application granted granted Critical
Publication of CN101657213B publication Critical patent/CN101657213B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200880012207.3A 2007-02-15 2008-02-15 用于增强t细胞应答的方法 Expired - Fee Related CN101657213B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90198007P 2007-02-15 2007-02-15
US60/901,980 2007-02-15
PCT/US2008/002044 WO2008100598A2 (en) 2007-02-15 2008-02-15 A method for enhancing t cell response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410026166.0A Division CN103736086A (zh) 2007-02-15 2008-02-15 用于增强t细胞应答的方法

Publications (2)

Publication Number Publication Date
CN101657213A CN101657213A (zh) 2010-02-24
CN101657213B true CN101657213B (zh) 2014-02-26

Family

ID=39690701

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880012207.3A Expired - Fee Related CN101657213B (zh) 2007-02-15 2008-02-15 用于增强t细胞应答的方法
CN201410026166.0A Pending CN103736086A (zh) 2007-02-15 2008-02-15 用于增强t细胞应答的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410026166.0A Pending CN103736086A (zh) 2007-02-15 2008-02-15 用于增强t细胞应答的方法

Country Status (9)

Country Link
US (1) US20080199485A1 (cg-RX-API-DMAC7.html)
EP (2) EP2481418A1 (cg-RX-API-DMAC7.html)
JP (2) JP5755839B2 (cg-RX-API-DMAC7.html)
CN (2) CN101657213B (cg-RX-API-DMAC7.html)
AU (1) AU2008216669B2 (cg-RX-API-DMAC7.html)
CA (1) CA2678353A1 (cg-RX-API-DMAC7.html)
ES (1) ES2527412T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009008620A (cg-RX-API-DMAC7.html)
WO (1) WO2008100598A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
EP2385059A3 (en) 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
CN101702917A (zh) 2007-03-30 2010-05-05 杜克大学 一种调节核酸分子活性的方法
WO2009155332A1 (en) 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
DE102008061522A1 (de) * 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2010075525A1 (en) * 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Method of using tumor cell debris to reduce brain tumor recurrence or growth
CN102639142A (zh) 2009-09-16 2012-08-15 杜克大学 内体Toll样受体活化的抑制
WO2011050344A2 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
ES2769326T3 (es) * 2010-02-05 2020-06-25 Univ Cornell Métodos y composiciones para la inmunoterapia contra el cáncer usando células tumorales que expresan la proteína de fusión de flagelina y antígeno asociado al tumor
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
US20150037374A1 (en) * 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
WO2015161094A1 (en) 2014-04-16 2015-10-22 Duke University Electrospun cationic nanofibers and methods of making and using the same
CA2978567A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation using plinabulin
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
WO2016183486A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
MX376122B (es) 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20190044029A (ko) 2016-05-18 2019-04-29 알버트 아인슈타인 컬리지 오브 메디슨, 인크. 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
WO2018119422A1 (en) 2016-12-22 2018-06-28 Duke University Polycationic microfibers and methods of using the same
DK3558339T5 (da) 2016-12-22 2024-09-02 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
CN110214192A (zh) * 2016-12-27 2019-09-06 中外制药株式会社 用于评价测试物质的免疫原性的方法
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
SG11202006985TA (en) 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
WO2019210055A2 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN111135310B (zh) * 2019-12-24 2021-05-07 江苏省人民医院（南京医科大学第一附属医院） 一种定制化t细胞表位疫苗的双靶向纳米药、其制备方法及应用
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN116262779A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1221349A (zh) * 1996-06-12 1999-06-30 郭亚军 细胞疫苗、免疫治疗以及它们的制备方法
WO2003103636A1 (en) * 2002-06-05 2003-12-18 Agresearch Limited A novel drug dosing regimen
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778879A (en) * 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4423392A1 (de) 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
JPH10512155A (ja) 1995-02-28 1998-11-24 マックス−プランク−ゲゼルシャフト ツル フェルデルング デアヴイッセンシャフテン エー．ファウ．ベルリン 癌およびその他の過形成を治療する薬剤
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
EP2286831A1 (en) 1997-07-10 2011-02-23 Mannkind Corporation A method of inducing a CTL response
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
DK1062341T3 (da) * 1998-03-16 2008-11-03 Alk Abello As Muterede rekombinante allergener
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20020165176A1 (en) * 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
CN100589845C (zh) * 2001-03-07 2010-02-17 麦康公司 用于治疗癌症的抗新血管系统制剂
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2003063770A2 (en) 2001-11-07 2003-08-07 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
MXPA05002455A (es) 2002-09-06 2005-06-03 Mannkind Corp Secuencias de epitopes.
MXPA05013973A (es) * 2003-06-17 2006-03-02 Mannkind Corp Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
CA2529056C (en) * 2003-06-17 2013-09-10 Mannkind Corporation Combinations of tumor-associated antigens in compositions for various types of cancers
US6997074B2 (en) 2003-10-30 2006-02-14 Eaton Corporation Prediction of destination gear for progressive shift feature
KR20070056042A (ko) * 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
JP2008526763A (ja) 2004-12-29 2008-07-24 マンカインド コーポレイション 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
JP2008526760A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
JP2008526764A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 免疫応答の誘導におけるｃｄ４＋細胞の回避方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1221349A (zh) * 1996-06-12 1999-06-30 郭亚军 细胞疫苗、免疫治疗以及它们的制备方法
WO2003103636A1 (en) * 2002-06-05 2003-12-18 Agresearch Limited A novel drug dosing regimen
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sivori S.等.CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumor and dendritic cells.《PNAS》.2004,第101卷(第27期),第10116页-第10121页. *

Also Published As

Publication number Publication date
CN103736086A (zh) 2014-04-23
EP2129389B1 (en) 2014-10-08
HK1141251A1 (en) 2010-11-05
ES2527412T3 (es) 2015-01-23
AU2008216669B2 (en) 2013-12-12
WO2008100598A2 (en) 2008-08-21
AU2008216669A1 (en) 2008-08-21
CN101657213A (zh) 2010-02-24
JP5755839B2 (ja) 2015-07-29
CA2678353A1 (en) 2008-08-21
US20080199485A1 (en) 2008-08-21
HK1139595A1 (en) 2010-09-24
JP2010519205A (ja) 2010-06-03
MX2009008620A (es) 2009-10-22
EP2129389A2 (en) 2009-12-09
WO2008100598A3 (en) 2008-12-31
JP2014043459A (ja) 2014-03-13
EP2481418A1 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
CN101657213B (zh) 用于增强t细胞应答的方法
Kayraklioglu et al. CpG oligonucleotides as vaccine adjuvants
JP2025061056A (ja) 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
ES2380796T3 (es) Oligonucleótidos inmunoestimuladores y sus usos.
Chiang et al. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines
Mutwiri et al. Biological activity of immunostimulatory CpG DNA motifs in domestic animals
Wu et al. Overview of vaccine adjuvants
Song et al. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity
Akache et al. Adjuvants: Engineering protective immune responses in human and veterinary vaccines
Lampe et al. High‐and low‐molecular‐weight chitosan act as adjuvants during single‐dose influenza A virus protein vaccination through distinct mechanisms
Kim et al. CpG‐ODN‐stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen‐specific antitumour immunity in a HPV 16 E7‐associated animal tumour model
JP2009544610A (ja) 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法
CA3028168C (en) Compositions and methods for activating antigen presenting cells with chimeric poliovirus
Jang et al. Dendritic cells stimulated with outer membrane protein A (OmpA) of Salmonella typhimurium generate effective anti-tumor immunity
CN106075432A (zh) 皮卡钙联合佐剂及含有皮卡钙联合佐剂的疫苗
AU2014201422B2 (en) A method for enhancing T cell response
HK1141251B (en) A method for enhancing t cell response
HK1174258A (en) A method for enhancing t cell response
HK1139595B (en) A method for enhancing t cell response
WO2023211279A1 (en) Adjuvant combinations for neopeptide vaccines
US20180055920A1 (en) Vaccine, therapeutic composition and methods for treating or inhibiting cancer
Mackiewicz et al. Vaccination and immunopharmacology
Pritz IC31® mediated induction of CD8 T cell responses
Mackiewicz Workshop U Vaccination and Immunopharmacology
Soema et al. Whole inactvated influenza virus as an adjuvant for influenza peptide antigens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141251

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1141251

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140226

Termination date: 20170215

CF01 Termination of patent right due to non-payment of annual fee